VeraDermics is a dermatology company that creates novel drug delivery mechanisms for a pain-free cure for skin conditions.
VeraDermics has raised $384.4M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in April 2026.
VeraDermics's investors include Connecticut Innovations, OUP (Osage University Partners), SR One, Longitude Capital, Invus.
VeraDermics is headquartered in New Haven, United States.
VeraDermics is a dermatology company that creates novel drug delivery mechanisms for a pain-free cure for skin conditions.
VeraDermics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"VeraDermics — Funding & Investors." VCBacked, April 29, 2026, https://www.vcbacked.co/company/veradermics. Accessed July 20, 2026.
VCBacked. (2026). VeraDermics — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/veradermics
{{cite web |title=VeraDermics — Funding & Investors |url=https://www.vcbacked.co/company/veradermics |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated